Inverness Bid to Buy Biosite Passes Federal Waiting Period | GenomeWeb
NEW YORK (GenomeWeb News) — Inverness Medical Innovations today said that the required waiting period has expired on its proposed offer to buy Biosite without the need for additional information.
The company said on May 18 it would acquire Biosite for $92.50 share after a protracted bidding war with Beckman Coulter ended in its favor.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Nature this week: genetic history of HIV in the US, and more.

There are a few projects aimed at addressing the lack of diversity in genomic research, Technology Review reports.

A national assessment shows that US students lag in the sciences, but suggests that achievement gaps are narrowing.

Harvard's George Church discusses HGP-write with the Journal of the American Medical Association.